There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Star Equity Holdings (STRR – Research Report), Evelo Biosciences (EVLO – Research Report) and 4D Molecular Therapeutics (FDMT – Research Report) with bullish sentiments.
Star Equity Holdings (STRR)
Maxim Group analyst Tate Sullivan maintained a Buy rating on Star Equity Holdings yesterday and set a price target of $2.25. The company’s shares closed last Thursday at $0.84, close to its 52-week low of $0.72.
According to TipRanks.com, Sullivan is a 5-star analyst with an average return of
Currently, the analyst consensus on Star Equity Holdings is a Moderate Buy with an average price target of $2.25.
See the top stocks recommended by analysts >>
Evelo Biosciences (EVLO)
In a report released yesterday, Gary Nachman from BMO Capital maintained a Buy rating on Evelo Biosciences, with a price target of $5.00. The company’s shares closed last Thursday at $0.30.
According to TipRanks.com, Nachman has 0 stars on 0-5 stars ranking scale with an average return of
Evelo Biosciences has an analyst consensus of Hold, with a price target consensus of $2.03.
4D Molecular Therapeutics (FDMT)
In a report released yesterday, Kostas Biliouris from BMO Capital maintained a Buy rating on 4D Molecular Therapeutics, with a price target of $50.00. The company’s shares closed last Thursday at $18.36.
According to TipRanks.com, Biliouris ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on 4D Molecular Therapeutics is a Strong Buy with an average price target of $38.00, representing an 118.8% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $36.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on STRR:
- Star Equity Holdings, Inc. Announces 2022 Fourth Quarter and Full Year Financial Results
- Star Equity reports Q4 adjusted EPS 14c vs 6c last year
- Star Equity Holdings, Inc. to Release Fourth Quarter and Full Year 2022 Financial Results on March 15th
- Star Equity Holdings, Inc. Declares Cash Dividend of $0.25 Per Share of 10% Series A Cumulative Perpetual Preferred Stock
